CSIMarket Company Name, Ticker, Suppliers, else..
 


In Vitro & In Vivo Diagnostic Substances Industry Growth Rates

Revenue, Income, Cash Flow and Capital Expenditure Growth Information & Trends 
 


Category:  

Download as CSV

In Vitro & In Vivo Diagnostic Substances Industry 3 Q 2 Q 1 Q 4 Q 3 Q
  Q3 2025 Q2 2025 Q1 2025 FY 2024 and Q4 2024 Q3 2024
Y / Y Revenue Quarterly Growth 8.03 % 4.17 % -0.12 % 3.39 % 4.67 %
Sequential Revenue Quarterly Growth -0.95 % 7.31 % -0.47 % -1.21 % 0.91 %
Revenue Growth Overall Ranking Y/Y # 40 # 58 # 71 # 56 # 37
Y / Y Revenue Annual Growth (at the end of Fiscal Year) 3.54 %
Y / Y Revenue Growth (12 Months at Quarter Ending) 5.07 % 5.35 % 4.02 % 3.54 % 4.61 %
Sequential Revenue Growth (12 Months at Quarter Ending) 1.95 % 1.07 % -0.03 % 0.69 % 1.07 %
Revenue Growth Ranking Y/Y (TTM) # 53 # 44 # 54 # 51 # 47
Y / Y Operating Income Quarterly Growth -13.06 % - - -85 % 20.95 %
Sequential Operating Income Quarterly Growth - - - -87.85 % 511.79 %
Operating Income Overall Ranking Y/Y # 40 # 58 # 71 # 56 # 41
Y / Y Operating Income Annual Growth (at the end of Fiscal Year) - - - -
Y / Y Operating Income Growth (12 Months trailing by quarter ending) -65.51 % - - - -
Sequential Operating Income Growth (12 Months trailing by quarter ending) -9.14 % - - - -
Operating Income Growth Ranking Y/Y (TTM) # 53 # 44 # 54 # 52 # 45
Y / Y Income from Cont. Ops Quarterly Growth -3.23 % - - - 26.4 %
Sequential Income from Cont. Ops Quarterly Growth - - - - -
Income from Cont. Ops Overall Ranking Y/Y # 40 # 58 # 71 # 56 # 41
Y / Y Income from Cont. Ops Annual Growth (at the end of Fiscal Year) - - - -
Y / Y Income from Cont. Ops Growth (12 Months trailing by quarter ending) -88.56 % - - - -
Sequential Income from Cont. Ops Growth (12 Months trailing by quarter ending) -7.07 % - - - -
Income from Cont. Ops Growth Ranking Y/Y (TTM) # 53 # 44 # 54 # 52 # 45
Y / Y Net Income Quarterly Growth -3.23 % - - - 26.4 %
Sequential Net Income Quarterly Growth - - - - -
Net Income Overall Ranking Y/Y # 40 # 58 # 71 # 56 # 41
Y / Y Net Income Annual Growth (at the end of Fiscal Year) - - - -
Y / Y Net Income Growth (12 Months trailing by quarter ending) -88.56 % - - - -
Sequential Net Income Growth (12 Months trailing by quarter ending) -7.07 % - - - -
Net Income Growth Ranking Y/Y (TTM) # 53 # 44 # 54 # 52 # 45
Y / Y Free Cash Flow Quarterly Growth 37.87 % -51.9 % 83.56 % 39.63 % 21.49 %
Sequential Free Cash Flow Quarterly Growth 79.48 % -9.36 % -51.56 % 0.59 % 137.86 %
Free Cash Flow Overall Ranking Y/Y # 40 # 58 # 71 # 56 # 41
Y / Y Free Cash Flow Annual Growth (at the end of Fiscal Year) 7.55 %
Y / Y Free Cash Flow Growth (12 Months trailing by quarter ending) 2.85 % -10.32 % 26 % 7.55 % -7.47 %
Sequential Free Cash Flow Growth (12 Months trailing by quarter ending) 5.06 % -13.75 % 1.49 % 5.14 % 1.38 %
Free Cash Flow Growth Ranking Y/Y (TTM) # 53 # 44 # 54 # 52 # 45
Y / Y Capital Expenditures Quarterly Growth -38.85 % -60.7 % -31.35 % 1.08 % 25.91 %
Sequential Capital Expenditures Quarterly Growth 35.89 % -18.24 % 7.08 % -23.79 % -10.13 %
Capital Expenditures Overall Ranking Y/Y # 40 # 58 # 71 # 56 # 41
Y / Y Capital Expenditures Annual Growth (at the end of Fiscal Year) 8.41 %
Y / Y Capital Expenditures Growth (12 Months trailing by quarter ending) -34.54 % -16.12 % -4.01 % 8.41 % -16.52 %
Sequential Capital Expenditures Growth (12 Months trailing by quarter ending) -15.14 % -11.25 % -9.49 % -1.78 % 7.41 %
Capital Expenditures Growth Ranking Y/Y (TTM) # 53 # 44 # 54 # 52 # 45

New: More In Vitro & In Vivo Diagnostic Substances Industrys' historic Revenue growth >>

Revenue growth Comment
In Vitro & In Vivo Diagnostic Substances Industry's pace of Revenue growth in 3 Q 2025 accelerated to 8.03 % year on year, but remained below Industry average.

Sequentially Revenue fell by -0.95 %.

Within Healthcare sector 3 other industries have accomplished higher Revenue growth. Revenue growth total ranking has improved so far to 40, from total ranking in previous quarter at 58.

 

Note, Numbers include only companies who have reported earnings results. Numbers change as more businesses report financial results. See the full List.



Revenue Y/Y Growth Statistics
High
Average
Low
84.1 % 10.34 % -98.79 %
1. quarter 2022
  
4. quarter 2021

Industry Revenue Y/Y Growth Ranking
Within: No.
Healthcare Sector # 4
Overall Market # 40



On the Trailing Twelve Months Basis In Vitro & In Vivo Diagnostic Substances Revenue Y/Y Growth

 


Revenue Y/Y TTM Growth Statistics
High
Average
Low
56.56 % 10.64 % -41.91 %
3. quarter 2022
  
4. quarter 2021

Revenue growth Y/Y TTM Comment
On the trailing twelve months basis
In Vitro & In Vivo Diagnostic Substances Industry's pace of Revenue growth in 3 Q 2025 decelerated to 5.07 % year on year, below In Vitro & In Vivo Diagnostic Substances Industry average.

Sequentially TTM Revenue grew by 1.95 %.

Within Healthcare sector 4 other industries have achieved higher Revenue growth. Revenue growth total ranking has declined compared to a quarter before from 44 to 53.

Industry Revenue Y/Y Growth Ranking Annual
Within: No.
Sector # 5
Overall Market # 53

In Vitro & In Vivo Diagnostic Substances Industry Operating Income Y/Y Growth

Operating Income growth Comment
In Vitro & In Vivo Diagnostic Substances Industry realized contraction in Operating Income by -13.06 % in 3 Q 2025 year on year.



Within Healthcare sector 3 other industries have accomplished higher Operating Income growth. Operating Income growth total ranking has improved so far to 40, from total ranking in previous quarter at 58.

 



Operating Income Y/Y Growth Statistics
High
Average
Low
84.1 % 10.34 % -98.79 %
1. quarter 2022
  
4. quarter 2021

Industry Operating Income Y/Y Growth Ranking
Within: No.
Healthcare Sector # 4
Overall Market # 40



On the Trailing Twelve Months Basis In Vitro & In Vivo Diagnostic Substances Operating Income Y/Y Growth

 


Operating Income Y/Y TTM Growth Statistics
High
Average
Low
56.56 % 10.64 % -41.91 %
3. quarter 2022
  
4. quarter 2021

Operating Income growth Y/Y TTM Comment
On the trailing twelve months basis
In Vitro & In Vivo Diagnostic Substances Industry faced contraction in cumulative twelve months Operating Income by -65.51 % in 3 Q 2025 year on year.



Within Healthcare sector 4 other industries have achieved higher Operating Income growth. Operating Income growth total ranking has declined compared to a quarter before from 44 to 53.

Industry Operating Income Y/Y Growth Ranking Annual
Within: No.
Sector # 5
Overall Market # 53

In Vitro & In Vivo Diagnostic Substances Industry Income from Cont. Ops Y/Y Growth

Income from Cont. Ops growth Comment
In Vitro & In Vivo Diagnostic Substances Industry realized contraction in Income from Cont. Ops by -3.23 % in 3 Q 2025 year on year.



Within Healthcare sector 3 other industries have accomplished higher Income from Cont. Ops growth. Income from Cont. Ops growth total ranking has improved so far to 40, from total ranking in previous quarter at 58.

 



Income from Cont. Ops Y/Y Growth Statistics
High
Average
Low
84.1 % 10.34 % -98.79 %
1. quarter 2022
  
4. quarter 2021

Industry Income from Cont. Ops Y/Y Growth Ranking
Within: No.
Healthcare Sector # 4
Overall Market # 40



On the Trailing Twelve Months Basis In Vitro & In Vivo Diagnostic Substances Income from Cont. Ops Y/Y Growth

 


Income from Cont. Ops Y/Y TTM Growth Statistics
High
Average
Low
56.56 % 10.64 % -41.91 %
3. quarter 2022
  
4. quarter 2021

Income from Cont. Ops growth Y/Y TTM Comment
On the trailing twelve months basis
In Vitro & In Vivo Diagnostic Substances Industry faced contraction in cumulative twelve months Income from Cont. Ops by -88.56 % in 3 Q 2025 year on year.



Within Healthcare sector 4 other industries have achieved higher Income from Cont. Ops growth. Income from Cont. Ops growth total ranking has declined compared to a quarter before from 44 to 53.

Industry Income from Cont. Ops Y/Y Growth Ranking Annual
Within: No.
Sector # 5
Overall Market # 53

In Vitro & In Vivo Diagnostic Substances Industry Net Income Y/Y Growth

Net Income growth Comment
In Vitro & In Vivo Diagnostic Substances Industry realized contraction in Net Income by -3.23 % in 3 Q 2025 year on year.



Within Healthcare sector 3 other industries have accomplished higher Net Income growth. Net Income growth total ranking has improved so far to 40, from total ranking in previous quarter at 58.

 



Net Income Y/Y Growth Statistics
High
Average
Low
84.1 % 10.34 % -98.79 %
1. quarter 2022
  
4. quarter 2021

Industry Net Income Y/Y Growth Ranking
Within: No.
Healthcare Sector # 4
Overall Market # 40



On the Trailing Twelve Months Basis In Vitro & In Vivo Diagnostic Substances Net Income Y/Y Growth

 


Net Income Y/Y TTM Growth Statistics
High
Average
Low
56.56 % 10.64 % -41.91 %
3. quarter 2022
  
4. quarter 2021

Net Income growth Y/Y TTM Comment
On the trailing twelve months basis
In Vitro & In Vivo Diagnostic Substances Industry faced contraction in cumulative twelve months Net Income by -88.56 % in 3 Q 2025 year on year.



Within Healthcare sector 4 other industries have achieved higher Net Income growth. Net Income growth total ranking has declined compared to a quarter before from 44 to 53.

Industry Net Income Y/Y Growth Ranking Annual
Within: No.
Sector # 5
Overall Market # 53

In Vitro & In Vivo Diagnostic Substances Industry Free Cash Flow Y/Y Growth

Free Cash Flow growth Comment
In Vitro & In Vivo Diagnostic Substances Industry's pace of Free Cash Flow growth in 3 Q 2025 accelerated to 37.87 % year on year, above Industry average.

Sequentially Free Cash Flow grew by 79.48 %.

Within Healthcare sector 3 other industries have accomplished higher Free Cash Flow growth. Free Cash Flow growth total ranking has improved so far to 40, from total ranking in previous quarter at 58.

 



Free Cash Flow Y/Y Growth Statistics
High
Average
Low
84.1 % 10.34 % -98.79 %
1. quarter 2022
  
4. quarter 2021

Industry Free Cash Flow Y/Y Growth Ranking
Within: No.
Healthcare Sector # 4
Overall Market # 40



On the Trailing Twelve Months Basis In Vitro & In Vivo Diagnostic Substances Free Cash Flow Y/Y Growth

 


Free Cash Flow Y/Y TTM Growth Statistics
High
Average
Low
56.56 % 10.64 % -41.91 %
3. quarter 2022
  
4. quarter 2021

Free Cash Flow growth Y/Y TTM Comment
On the trailing twelve months basis
In Vitro & In Vivo Diagnostic Substances Industry's pace of cumulative 12 months Free Cash Flow growth in 3 Q 2025 accelerated to 2.85 % year on year, but remained below Industry average.

Sequentially TTM Free Cash Flow grew by 5.06 %.

Within Healthcare sector 4 other industries have achieved higher Free Cash Flow growth. Free Cash Flow growth total ranking has declined compared to a quarter before from 44 to 53.

Industry Free Cash Flow Y/Y Growth Ranking Annual
Within: No.
Sector # 5
Overall Market # 53

In Vitro & In Vivo Diagnostic Substances Industry Capital Expenditures Y/Y Growth

Capital Expenditures growth Comment
In Vitro & In Vivo Diagnostic Substances Industry realized contraction in Capital Expenditures by -38.85 % in 3 Q 2025 year on year.

Sequentially Capital Expenditures grew by 35.89 %.

Within Healthcare sector 3 other industries have accomplished higher Capital Expenditures growth. Capital Expenditures growth total ranking has improved so far to 40, from total ranking in previous quarter at 58.

 



Capital Expenditures Y/Y Growth Statistics
High
Average
Low
84.1 % 10.34 % -98.79 %
1. quarter 2022
  
4. quarter 2021

Industry Capital Expenditures Y/Y Growth Ranking
Within: No.
Healthcare Sector # 4
Overall Market # 40



On the Trailing Twelve Months Basis In Vitro & In Vivo Diagnostic Substances Capital Expenditures Y/Y Growth

 


Capital Expenditures Y/Y TTM Growth Statistics
High
Average
Low
56.56 % 10.64 % -41.91 %
3. quarter 2022
  
4. quarter 2021

Capital Expenditures growth Y/Y TTM Comment
On the trailing twelve months basis
In Vitro & In Vivo Diagnostic Substances Industry faced contraction in cumulative twelve months Capital Expenditures by -34.54 % in 3 Q 2025 year on year.

Sequentially cumulative Capital Expenditures fell by -15.14 %.

Within Healthcare sector 4 other industries have achieved higher Capital Expenditures growth. Capital Expenditures growth total ranking has declined compared to a quarter before from 44 to 53.

Industry Capital Expenditures Y/Y Growth Ranking Annual
Within: No.
Sector # 5
Overall Market # 53





Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.